Atossa Therapeutics, Inc. (ATOS) DCF Valuation

Atossa Therapeutics, Inc. (ATOS) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Atossa Therapeutics, Inc. (ATOS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of Atossa Therapeutics, Inc.? Our ATOS DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your projections and make more informed investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -17.2 -14.6 -20.5 -27.7 -31.4 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .1 .0 .0 .0 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -17.3 -14.6 -20.5 -27.7 -31.4 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 12.6 39.6 136.4 110.9 88.5 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .7 .6 1.1 .7 .0
Account Receivables, % 100 100 100 100 100
Inventories 1.0 1.9 2.6 4.1 1.5 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .3 1.6 1.7 3.0 .8 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -17.3 -17.3 -20.5 -26.9 -31.4 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -18.6 -16.8 -21.5 -26.9 -30.1 .7 .0 .0 .0 .0
WACC, % 10.27 10.27 10.27 10.27 10.27 10.27 10.27 10.27 10.27 10.27
PV UFCF
SUM PV UFCF .6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 1
Net Debt -88
Equity Value 89
Diluted Shares Outstanding, MM 126
Equity Value Per Share 0.71

What You Will Get

  • Comprehensive ATOS Financials: Access both historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
  • Scenario Analysis: Explore various scenarios to assess Atossa Therapeutics' potential performance.
  • User-Friendly Design: Designed for professionals while remaining approachable for newcomers.

Key Features

  • Current ATOS Data: Pre-filled with Atossa Therapeutics’ historical financials and future projections.
  • Customizable Metrics: Modify revenue growth rates, profit margins, discount rates, tax assumptions, and capital investments.
  • Interactive Valuation Model: Automatically refreshes Net Present Value (NPV) and intrinsic value based on user inputs.
  • Scenario Analysis: Develop various forecasting scenarios to explore different valuation possibilities.
  • Intuitive Interface: Designed to be straightforward and accessible for both professionals and newcomers.

How It Works

  • Step 1: Download the prebuilt Excel template containing Atossa Therapeutics, Inc.'s (ATOS) data.
  • Step 2: Review the pre-filled sheets to grasp the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly access recalculated results, including Atossa Therapeutics, Inc.'s (ATOS) intrinsic value.
  • Step 5: Make informed investment decisions or create reports utilizing the outputs.

Why Choose Atossa Therapeutics, Inc. (ATOS)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs in breast cancer treatment.
  • Commitment to Research: Robust clinical trials backed by scientific rigor ensure the highest levels of accuracy.
  • Patient-Centric Approach: Focused on improving patient outcomes through personalized medicine.
  • Experienced Team: Led by a team of experts with extensive knowledge in biotechnology and pharmaceuticals.
  • Proven Track Record: Trusted by investors and healthcare professionals for our dedication to advancing treatment options.

Who Should Use Atossa Therapeutics, Inc. (ATOS)?

  • Investors: Gain insights into the biotech sector with a cutting-edge analysis tool.
  • Financial Analysts: Streamline your research with comprehensive data on Atossa's market performance.
  • Consultants: Easily customize the information for client strategies or investment recommendations.
  • Biotech Enthusiasts: Enhance your knowledge of innovative therapies and their market potential.
  • Educators and Students: Utilize it as a resource for case studies in biotechnology and finance courses.

What the Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations specific to Atossa Therapeutics, Inc. (ATOS).
  • Real-World Data: Atossa’s historical and projected financials preloaded for in-depth analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore different scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
  • Dashboard with Visual Outputs: Charts and tables providing clear, actionable results.

No products were found matching.